NCT07517874 (GLOW-Safety-4) is a NA clinical trial of Mitopure Topical Formula 11 in Irritation/Irritant, sponsored by Amazentis SA.

Who is sponsoring NCT07517874?

NCT07517874 is sponsored by Amazentis SA.

What drugs are being tested in NCT07517874?

Interventions in NCT07517874: Mitopure Topical Formula 11.

What condition does NCT07517874 study?

NCT07517874 studies Irritation/Irritant, Sensitisation.

Is NCT07517874 still recruiting?

NCT07517874 is currently not yet recruiting. Last updated 8 April 2026.

Last reviewed 2026-04-08 · How we verify

NCT07517874: GLOW-Safety-4

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Human Skin Safety Testing of 1 Mitopure Topical Products Using a Human Repeat Insult Patch Test (HRIPT) in Healthy Volunteers

Not yet recruiting NA Last updated 8 April 2026

What this trial tests

NA trial testing Mitopure Topical Formula 11 in Irritation/Irritant in 100 participants. Not yet recruiting.

Timeline

1 May 2026

Primary endpoint
15 September 2026

15 September 2026

Quick facts

Lead sponsor	Amazentis SA
Phase	NA
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	basic science
Enrollment	100
Start date	1 May 2026
Primary completion	15 September 2026
Estimated completion	15 September 2026
Sites	1 location across United Kingdom

Drugs / interventions tested

Mitopure Topical Formula 11

Conditions studied

Irritation/Irritant — all drugs for Irritation/Irritant →
Sensitisation — all drugs for Sensitisation →

Sponsor

Amazentis SA — full company profile →

Who can join

18 and older, any sex, with Irritation/Irritant or Sensitisation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to investigate the irritation and sensitization potential of 1 topically applied test article containing Mitopure in a shared panel of healthy volunteers by means of repeated cutaneous patch applications under occlusion based on the modified Draize method

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Amazentis SA trials

Trials by the same sponsor.

NCT07517913 — Cerebrospinal Fluid Kinetics of Urolithin A · NA · not yet recruiting
NCT07517887 — Anti-aging Efficacy Study on One Cosmetic Product Containing Mitopure · NA · not yet recruiting
NCT07517900 — Human Skin Safety Testing of 1 Mitopure Topical Product Using a Clinical Safety in Use Study in Healthy Volunteers · NA · not yet recruiting
NCT07231783 — The Effect of Urolithin A (Mitopure®) Supplementation on Muscle Strength in Healthy Middle-Aged Adults · NA · recruiting
NCT07231848 — Bioavailability of Four Mitopure Formulations · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07517874 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Amazentis SA
Last refreshed: 8 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07517874.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing